Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Public ClinicalTrials.gov record NCT05052801. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Study identification
- NCT ID
- NCT05052801
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 547 participants
Conditions and interventions
Interventions
- Bemarituzumab Drug
- mFOLFOX6 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2022
- Primary completion
- Jun 19, 2025
- Completion
- Apr 25, 2026
- Last update posted
- May 26, 2026
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology | Anchorage | Alaska | 99508 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| The Oncology Institute Clinical Research | Cerritos | California | 90703 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Saint Francis Medical Group | Indianapolis | Indiana | 46237 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Healthier Hematology and Oncology Excelsior Integrated Medical Group | Brooklyn | New York | 11220 | — |
| White Plains Hospital Center for Cancer Care | White Plains | New York | 10601 | — |
| Levine Cancer Institute University | Charlotte | North Carolina | 28204 | — |
| FirstHealth Cancer Center | Pinehurst | North Carolina | 28374 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57108 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Medical Oncology Associates, PS | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 284 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05052801, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05052801 live on ClinicalTrials.gov.